BriaCell Therapeutics Corp. is a clinical stage immuno-oncology company that is actively developing innovative targeted cellular immunotherapies to revolutionize cancer care. With lead candidates such as Bria-IMT™ and Bria-OTS™ in pivotal Phase 3 and Phase 1/2 clinical studies, respectively, the company is positioned at a critical growth stage as it navigates through advanced research and regulatory milestones towards commercialization and market adoption.

BriaCell has achieved significant milestones in its journey towards transforming cancer treatment. These milestones include obtaining Fast Track status from the FDA for Bria-IMT™, awarding numerous US and international patents for Bria-OTS™, initiating patient enrollment in Phase 1/2 clinical trials for various cancers, receiving a Small Business Innovation Research (SBIR) award from the National Cancer Institute, and planning to launch an enhanced version of Bria-OTS™, Bria-OTS+™, in the clinic by 2025. These milestones signify the company's progress in developing cutting-edge immunotherapies and expanding its portfolio to address a broad range of cancer types.

BriaCell Therapeutics Corp. has been involved in several notable case studies and projects that highlight the impact of its immunotherapies on cancer treatment. The clinical data from Phase 2 studies of Bria-IMT™ demonstrated significant survival benefits and clinical responses in heavily pre-treated metastatic breast cancer patients, including those resistant to traditional therapies. Moreover, the innovative design of Bria-OTS™, with its ability to match personalized treatments to over 99% of patients through a simple saliva test, showcases the company's commitment to advancing precision medicine in oncology. These case studies emphasize the potential of BriaCell's novel immunotherapies to transform the standard of care for cancer patients.

BriaCell Therapeutics Corp. has been actively engaged in key events that have propelled its growth and visibility in the field of immuno-oncology. From securing Fast Track designation for Bria-IMT™ to launching pivotal Phase 3 studies in metastatic breast cancer, the company has demonstrated a strategic focus on advancing its lead drug candidates towards regulatory approval. The initiation of Phase 1/2 bucket trials for Bria-OTS™ across multiple cancer types, including breast, prostate, lung, and melanoma, underscores the company's commitment to addressing unmet medical needs and expanding its therapeutic reach. Furthermore, receiving a Small Business Innovation Research (SBIR) award and collaborating with the National Cancer Institute highlight BriaCell's credibility and expertise in developing cutting-edge cancer immunotherapies.